Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
08/2003
08/21/2003US20030158219 N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
08/21/2003US20030158209 Amidomethylcarbonyl-substituted piperazine derivatives containing additional amine groups, useful in treating eating, sexual and skin disorders
08/21/2003US20030158202 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders
08/21/2003US20030158197 Certain alkylene diamine-substituted heterocycles
08/21/2003US20030158189 Non-steroidal antiinflammatory agents treating bone disorders, Crohn's disease, and inflammatory bowel disease, respiratory disorders such as chronic obstructive pulmonary disease, infections, autoimmune diseases
08/21/2003US20030158179 Quinoline derivatives
08/21/2003US20030158173 NK 1 antagonists
08/21/2003US20030158162 Administering a therapeutically effective amount of an epoxy-steroidal aldosterone receptor antagonist that contains a 9,11-epoxy group to the patient for reducing intraocular pressure
08/21/2003US20030158122 For treatment of hyperlipidemia and blood coagulation disorders and to reduce levels of virus, bacteria, and endotoxins in blood stream
08/21/2003US20030158119 Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on
08/21/2003US20030158113 Administering to individual a therapeutically effective amount of osteopontin or a functional fragment
08/21/2003US20030158094 Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product
08/21/2003US20030158085 For diagnosis and therapy of pancreatic disorders, particularly type I diabetes
08/21/2003US20030158081 Genetic polymorphisms in the human HMG-CoA reductase gene and their use in diagnosis and treatment of diseases
08/21/2003US20030157552 Providing a screening assay having stearoyl-CoA desaturase biological activity, contacting sceening assay with a test compound and measuring the biological activity
08/21/2003US20030157225 Food product and process
08/21/2003US20030157144 Desaturase genes and uses thereof
08/21/2003US20030157138 Pharmaceutical or cosmetic carrier or composition for topical application onto skin and/or mucosal membranes; treatment of skin diseases or disorders including eczema, psoriasis and dermatitis
08/21/2003US20030157108 80-100% of the glycoprotein has a mature core carbohydrate structure which lacks fucose, attached to a Fc region
08/21/2003US20030157107 Agents for preventing or ameliorating insulin resistance and/or obesity
08/21/2003US20030157084 Methods for preparing purified prostaglandin E synthase
08/21/2003CA2476553A1 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
08/21/2003CA2476120A1 Methods and compositions for the treatment of eye diseases
08/21/2003CA2476027A1 Alpha-substituted arylalkyl phosphonate derivatives
08/21/2003CA2476017A1 Preparations containing folic acid, vitamin b6, and vitamin b12, and use thereof
08/21/2003CA2475882A1 Alpha-substituted heteroarylalkyl phosphonate derivatives
08/21/2003CA2475783A1 Benzenesulfonamide derivatives as antipsychotic agents
08/21/2003CA2475770A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn.gamma.g(g)
08/21/2003CA2475722A1 Formulations of atorvastatin stabilized with alkali metal additions
08/21/2003CA2475708A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003CA2475703A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003CA2475544A1 Oral dosage form for controlled drug release
08/21/2003CA2475439A1 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003CA2475338A1 Treatment of ophthalmic disorders using urea and urea derivatives
08/21/2003CA2472822A1 Chemical compounds
08/21/2003CA2452854A1 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
08/20/2003EP1336607A1 Amide derivatives as glucokinase activators
08/20/2003EP1336600A2 Dimer-selective RXR modulators and methods for their use
08/20/2003EP1336413A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
08/20/2003EP1336405A1 Formulations of atorvastatin stabilized with alkali metal additions
08/20/2003EP1335976A2 Modifier of organelle metalbolism
08/20/2003EP1335933A2 Pna analogues
08/20/2003EP1335914A1 Triazole derivatives and pharmaceutical compositions comprising them
08/20/2003EP1335912A1 4-(biphenylcarbonylamino)piperidine derivatives as mtp inhibitors
08/20/2003EP1335908A2 Peroxisome proliferator activated receptor alpha agonists
08/20/2003EP1335907A1 Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
08/20/2003EP1335906A1 Pyrimidine derivatives and their use as neuropeptide y receptor ligands
08/20/2003EP1335741A2 METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
08/20/2003EP1335738A2 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
08/20/2003EP1335736A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders
08/20/2003EP1335731A2 Antidiabetic compositions containing a biguanide and a sulfonamide
08/20/2003EP1335720A1 Sulphonamides for the treatment of central nervous system diseases
08/20/2003EP1335708A1 Controlled release metformin compositions
08/20/2003EP1335701A2 Anti-adiposis topical treatment composition based on garlic bulb extracts
08/20/2003EP1335693A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
08/20/2003EP1254139B1 4-heteroaryl-1,4-diazabicyclo 3.2.2]nonane, preparation and therapeutic use thereof
08/20/2003EP1239836B1 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same
08/20/2003EP1212327B1 Pyrazolopyrimidines as therapeutic agents
08/20/2003EP1173434B1 Thiazolidinedione derivative and its use as antidiabetic
08/20/2003EP1086106B1 Furopyridine derivatives and their therapeutical use
08/20/2003EP1075258B1 Novel fatty analogues for the treatment of obesity
08/20/2003EP0966295B1 Calcareous material
08/20/2003EP0900083B1 Novel substituted imidazole compounds
08/20/2003EP0865288B1 Bioartificial devices and cellular matrices therefor
08/20/2003CN2566851Y Nano-insulin oral preparation
08/20/2003CN1437608A O-aryl glucoside SGL T2 inhibitors and method
08/20/2003CN1437599A Tryasolyl tropane derivatives for therapy
08/20/2003CN1437591A Compounds and methods for modulation of estrogen receptors
08/20/2003CN1437588A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type l
08/20/2003CN1437587A Benzoxazepinones and their use as squalene synthase inhibitors
08/20/2003CN1437584A Tricyclic protein kinase inhibitors
08/20/2003CN1437581A Glucagon antagonists/inverse agonists
08/20/2003CN1437484A New formulation comprising a beta-blocker and optionally a cholesterol-lowering agent
08/20/2003CN1437483A Oral preparations for diabetes
08/20/2003CN1437464A Improved water-insoluble drug particle process
08/20/2003CN1437441A Novel diphenylethylene compound
08/20/2003CN1436541A Diabetes treating medicine
08/20/2003CN1436539A Efficient Fe-Zn-Ca health product for nourishing blood and replenishing calcium and its production process
08/20/2003CN1436538A Effervescent pearl calcium tablet and its prepn process
08/20/2003CN1436527A Glimepiride dripping pills
08/20/2003CN1118467C 1,3,8-triaza-spiro [4,5] decan-4-on derivatives
08/20/2003CN1118462C Substituted phenyl derivatives, producing method and use thereof
08/20/2003CN1118457C Cyclic diamine compound and medicine containing the same
08/20/2003CN1118450C Novel L-threonic acid derivatives
08/20/2003CN1118287C Health-care medicine
08/20/2003CN1118282C Method for preparing calcium replenishing liquid with composite function
08/20/2003CN1118248C Method for producing fat mixture
08/19/2003US6608218 Such as 1-(cyclopentyloxy-(3,4-dichloro-phenyl)-acetyl)-3-methyl-urea for treatment of diabetes
08/19/2003US6608203 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
08/19/2003US6608182 Human vascular endothelial growth factor 2
08/19/2003US6608107 Administering gossypol; kits to treat patients
08/19/2003US6608104 Gem substituted hydroxamic acids
08/19/2003US6608101 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
08/19/2003US6608098 Isoindole derivatives
08/19/2003US6608083 Treatment and/or prophylaxis of convulsive disorders, renal disorders, urinary incontinence, ocular inflammation, eating disorders, inflammatory pain, allergic rhinitis, psoriasis,neurodegenerative disorders, Huntington's disease,
08/19/2003US6608063 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
08/19/2003US6608044 Inhibition of TNF activity
08/19/2003US6608032 Medicinal compositions
08/19/2003US6608031 Peptide comprising specified amino acid sequence
08/19/2003US6608030 Inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence
1 ... 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 ... 1298